Thymidylate synthase and DNA

Combined TS inhibition + DNA cross-linking refers to a multi-targeted therapeutic strategy rather than a single biological molecule. This approach involves the simultaneous inhibition of the enzyme thymidylate synthase (TYMS) and the induction of covalent cross-links within the DNA structure [1, 2]. Thymidylate synthase is a critical enzyme in the de novo synthesis of thymidine monophosphate (dTMP), and its inhibition leads to the depletion of deoxythymidine triphosphate (dTTP) pools, thereby stalling DNA replication and repair [1]. Concurrently, DNA cross-linking agents, such as platinum-based compounds (e.g., oxaliplatin, cisplatin), form intra-strand and inter-strand adducts that physically obstruct DNA polymerase and RNA polymerase activity [2, 3]. The synergy between these two mechanisms enhances cytotoxicity by both starving the cell of necessary nucleotides and creating physical barriers to genomic integrity, ultimately triggering apoptosis [3, 4]. This dual-action profile is most commonly achieved through combination chemotherapy regimens like FOLFOX or FOLFIRI, though certain next-generation nucleoside analogs are designed to mimic aspects of this multi-modal attack [4].

Other names

Combined TS inhibition + DNA cross-linkingTS inhibition and DNA cross-linkingDual TS/DNA targetingThymidylate synthase inhibition and DNA adduct formation

Simultaneous inhibition of thymidylate synthase to deplete thymidine pools and chemical cross-linking of DNA to block replication.